# WuXi Biologics

全球CDMO巨头——开放式生物制品平台，覆盖从IND申报到商业生产的细胞系开发；营收25亿美元；四大洲14个GMP基地；港交所：2269.HK；友好供应商。

Source: https://cn.bioecon.ru/companies/wuxi-biologics/
Updated: 2026-06-19

- 国家: China
- 营收: RMB 18.7B
- 员工: ~14,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 人民币218亿 (2025-12-31) | https://www.prnewswire.com/news-releases/wuxi-biologics-reports-record-2025-annual-results-302723294.html, https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-record-2025-annual-results/ |
| 营收 | 人民币118亿（2026年上半年） (2026-06-30) | https://www.prnewswire.com/news-releases/wuxi-biologics-reports-strong-profitable-growth-in-h1-2026-302859399.html, https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-strong-profitable-growth-in-h1-2026/ |
| 产能 | 生物反应器产能超过260,000升，计划提升至580,000升以上 (2025-01-09) | https://www.wuxibiologics.com/capabilities/commercial-ds-manufacturing/ |
| 生产基地 | 15个GMP认证生产基地 (2026-06-30) | https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-strong-profitable-growth-in-h1-2026/ |
| 认证 | 获得166项设施许可；自2017年以来接受美国FDA、欧盟EMA及NMPA等机构49次监管检查，通过率100% (2026-08-31) | https://megaproject.com/news/factory/wuxi-biologics-accelerates-development-manufacturing-with-robust-model-platforms, https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-record-2025-annual-results/, https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-strong-profitable-growth-in-h1-2026/ |
| 员工人数 | 全球14,705名员工 (2026-06-30) | https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-record-2025-annual-results/, https://www.wuxibiologics.com/press-release/wuxi-biologics-reports-strong-profitable-growth-in-h1-2026/ |

独立来源: megaproject.com, prnewswire.com

## 技术

- [生物生产 CDMO/CMO (生物制剂/ATMP/mRNA)](https://cn.bioecon.ru/technology/bioproduction-cdmo-cmo/)
- [生物药 (Biologics)](https://cn.bioecon.ru/technology/biologics/)
- [面向市场准入的本地化生产](https://cn.bioecon.ru/technology/local-manufacturing-for-market-access/)